Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Redirected T Cell Cytotoxicity in Cancer Therapy.

Clynes RA, Desjarlais JR.

Annu Rev Med. 2019 Jan 27;70:437-450. doi: 10.1146/annurev-med-062617-035821. Epub 2018 Oct 31.

PMID:
30379598
2.

High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata.

de Jong A, Jabbari A, Dai Z, Xing L, Lee D, Li MM, Duvic M, Hordinsky M, Norris DA, Price V, Mackay-Wiggan J, Clynes R, Christiano AM.

JCI Insight. 2018 Oct 4;3(19). pii: 121949. doi: 10.1172/jci.insight.121949.

3.

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.

Norton N, Fox N, McCarl CA, Tenner KS, Ballman K, Erskine CL, Necela BM, Northfelt D, Tan WW, Calfa C, Pegram M, Colon-Otero G, Perez EA, Clynes R, Knutson KL.

Breast Cancer Res. 2018 Jun 14;20(1):52. doi: 10.1186/s13058-018-0989-8.

4.

An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.

Jabbari A, Sansaricq F, Cerise J, Chen JC, Bitterman A, Ulerio G, Borbon J, Clynes R, Christiano AM, Mackay-Wiggan J.

J Invest Dermatol. 2018 Jul;138(7):1539-1545. doi: 10.1016/j.jid.2018.01.032. Epub 2018 Feb 13.

5.

Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.

Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise JE, Clark C, Ulerio G, Furniss M, Vaughan R, Christiano AM, Clynes R.

JCI Insight. 2016 Sep 22;1(15):e89790. doi: 10.1172/jci.insight.89790.

6.

CXCR3 Blockade Inhibits T Cell Migration into the Skin and Prevents Development of Alopecia Areata.

Dai Z, Xing L, Cerise J, Wang EH, Jabbari A, de Jong A, Petukhova L, Christiano AM, Clynes R.

J Immunol. 2016 Aug 15;197(4):1089-99. doi: 10.4049/jimmunol.1501798. Epub 2016 Jul 13.

7.

Molecular signatures define alopecia areata subtypes and transcriptional biomarkers.

Jabbari A, Cerise JE, Chen JC, Mackay-Wiggan J, Duvic M, Price V, Hordinsky M, Norris D, Clynes R, Christiano AM.

EBioMedicine. 2016 May;7:240-7. doi: 10.1016/j.ebiom.2016.03.036. Epub 2016 Mar 31.

8.

Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain.

Knutson KL, Clynes R, Shreeder B, Yeramian P, Kemp KP, Ballman K, Tenner KS, Erskine CL, Norton N, Northfelt D, Tan W, Calfa C, Pegram M, Mittendorf EA, Perez EA.

Cancer Res. 2016 Jul 1;76(13):3702-10. doi: 10.1158/0008-5472.CAN-15-3091. Epub 2016 Apr 20.

9.

Mechanisms and Disease Associations of Haplotype-Dependent Allele-Specific DNA Methylation.

Do C, Lang CF, Lin J, Darbary H, Krupska I, Gaba A, Petukhova L, Vonsattel JP, Gallagher MP, Goland RS, Clynes RA, Dwork A, Kral JG, Monk C, Christiano AM, Tycko B.

Am J Hum Genet. 2016 May 5;98(5):934-955. doi: 10.1016/j.ajhg.2016.03.027.

10.

Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers.

Jabbari A, Nguyen N, Cerise JE, Ulerio G, de Jong A, Clynes R, Christiano AM, Mackay-Wiggan J.

Exp Dermatol. 2016 Aug;25(8):642-3. doi: 10.1111/exd.13060. No abstract available.

11.

Novel technologies and emerging biomarkers for personalized cancer immunotherapy.

Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, Kvistborg P, Maccalli C, Maecker HT, Page DB, Robins H, Song W, Stack EC, Wang E, Whiteside TL, Zhao Y, Zwierzina H, Butterfield LH, Fox BA.

J Immunother Cancer. 2016 Jan 19;4:3. doi: 10.1186/s40425-016-0107-3. eCollection 2016. Review.

12.

Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA).

Harris JE, Rashighi M, Nguyen N, Jabbari A, Ulerio G, Clynes R, Christiano AM, Mackay-Wiggan J.

J Am Acad Dermatol. 2016 Feb;74(2):370-1. doi: 10.1016/j.jaad.2015.09.073. Epub 2015 Dec 11. No abstract available.

13.

Master regulators of infiltrate recruitment in autoimmune disease identified through network-based molecular deconvolution.

Chen JC, Cerise JE, Jabbari A, Clynes R, Christiano AM.

Cell Syst. 2015 Nov 25;1(5):326-337.

14.

Pharmacologic inhibition of JAK-STAT signaling promotes hair growth.

Harel S, Higgins CA, Cerise JE, Dai Z, Chen JC, Clynes R, Christiano AM.

Sci Adv. 2015 Oct 23;1(9):e1500973. doi: 10.1126/sciadv.1500973. eCollection 2015 Oct.

15.

Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.

Jabbari A, Dai Z, Xing L, Cerise JE, Ramot Y, Berkun Y, Sanchez GA, Goldbach-Mansky R, Christiano AM, Clynes R, Zlotogorski A.

EBioMedicine. 2015 Feb 26;2(4):351-5. doi: 10.1016/j.ebiom.2015.02.015. eCollection 2015 Apr.

16.

Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.

Flynn R, Allen JL, Luznik L, MacDonald KP, Paz K, Alexander KA, Vulic A, Du J, Panoskaltsis-Mortari A, Taylor PA, Poe JC, Serody JS, Murphy WJ, Hill GR, Maillard I, Koreth J, Cutler CS, Soiffer RJ, Antin JH, Ritz J, Chao NJ, Clynes RA, Sarantopoulos S, Blazar BR.

Blood. 2015 Jun 25;125(26):4085-94. doi: 10.1182/blood-2014-08-595470. Epub 2015 Apr 7.

17.

FcγRIIB prevents inflammatory type I IFN production from plasmacytoid dendritic cells during a viral memory response.

Flores M, Chew C, Tyan K, Huang WQ, Salem A, Clynes R.

J Immunol. 2015 May 1;194(9):4240-50. doi: 10.4049/jimmunol.1401296. Epub 2015 Mar 27.

18.

Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci.

Betz RC, Petukhova L, Ripke S, Huang H, Menelaou A, Redler S, Becker T, Heilmann S, Yamany T, Duvic M, Hordinsky M, Norris D, Price VH, Mackay-Wiggan J, de Jong A, DeStefano GM, Moebus S, Böhm M, Blume-Peytavi U, Wolff H, Lutz G, Kruse R, Bian L, Amos CI, Lee A, Gregersen PK, Blaumeiser B, Altshuler D, Clynes R, de Bakker PIW, Nöthen MM, Daly MJ, Christiano AM.

Nat Commun. 2015 Jan 22;6:5966. doi: 10.1038/ncomms6966.

19.

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, de Jong A, Harel S, DeStefano GM, Rothman L, Singh P, Petukhova L, Mackay-Wiggan J, Christiano AM, Clynes R.

Nat Med. 2014 Sep;20(9):1043-9. doi: 10.1038/nm.3645. Epub 2014 Aug 17.

20.

Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.

Norton N, Olson RM, Pegram M, Tenner K, Ballman KV, Clynes R, Knutson KL, Perez EA.

Cancer Immunol Res. 2014 Oct;2(10):962-9. doi: 10.1158/2326-6066.CIR-14-0059. Epub 2014 Jul 2.

21.

ILT3.Fc inhibits the production of exosomes containing inflammatory microRNA in supernatants of alloactivated T cells.

Xu Z, Ho S, Chang CC, Liu Z, Li M, Vasilescu ER, Clynes RA, Vlad G, Suciu-Foca N.

Hum Immunol. 2014 Aug;75(8):756-9. doi: 10.1016/j.humimm.2014.05.006. Epub 2014 May 24.

PMID:
24862932
22.

The receptor for advanced glycation end products (RAGE) affects T cell differentiation in OVA induced asthma.

Akirav EM, Henegariu O, Preston-Hurlburt P, Schmidt AM, Clynes R, Herold KC.

PLoS One. 2014 Apr 23;9(4):e95678. doi: 10.1371/journal.pone.0095678. eCollection 2014.

23.

Detection of donor-specific-antibodies by solid phase assay and its relevance to complement-dependent-lymphocytotoxicity cross-matching in kidney transplantation.

Ho EK, Vasilescu ER, Vlad G, Clynes RA, Ratner LE, Suciu-Foca N.

Hum Immunol. 2014 Jun;75(6):520-3. doi: 10.1016/j.humimm.2014.03.002. Epub 2014 Mar 21.

PMID:
24662417
24.

Allospecific CD8 T suppressor cells induced by multiple MLC stimulation or priming in the presence of ILT3.Fc have similar gene expression profiles.

Chen L, Xu Z, Chang C, Ho S, Liu Z, Vlad G, Cortesini R, Clynes RA, Luo Y, Suciu-Foca N.

Hum Immunol. 2014 Feb;75(2):190-6. doi: 10.1016/j.humimm.2013.10.004. Epub 2013 Nov 9.

PMID:
24220571
25.

Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells.

Henle AM, Erskine CL, Benson LM, Clynes R, Knutson KL.

J Immunol. 2013 Jan 1;190(1):479-88. doi: 10.4049/jimmunol.1201264. Epub 2012 Nov 23.

26.

Genetic basis of alopecia areata: a roadmap for translational research.

Jabbari A, Petukhova L, Cabral RM, Clynes R, Christiano AM.

Dermatol Clin. 2013 Jan;31(1):109-17. doi: 10.1016/j.det.2012.08.014. Epub 2012 Oct 23. Review.

27.

RAGE expression in human T cells: a link between environmental factors and adaptive immune responses.

Akirav EM, Preston-Hurlburt P, Garyu J, Henegariu O, Clynes R, Schmidt AM, Herold KC.

PLoS One. 2012;7(4):e34698. doi: 10.1371/journal.pone.0034698. Epub 2012 Apr 11.

28.

Downregulation of inflammatory microRNAs by Ig-like transcript 3 is essential for the differentiation of human CD8(+) T suppressor cells.

Chang CC, Zhang QY, Liu Z, Clynes RA, Suciu-Foca N, Vlad G.

J Immunol. 2012 Apr 1;188(7):3042-52. doi: 10.4049/jimmunol.1102899. Epub 2012 Mar 2.

29.

The genetics of alopecia areata: What's new and how will it help our patients?

Petukhova L, Cabral RM, Mackay-Wiggan J, Clynes R, Christiano AM.

Dermatol Ther. 2011 May-Jun;24(3):326-36. doi: 10.1111/j.1529-8019.2011.01411.x.

PMID:
21689242
30.

A requirement for the p85 PI3K adapter protein BCAP in the protection of macrophages from apoptosis induced by endoplasmic reticulum stress.

Song S, Chew C, Dale BM, Traum D, Peacock J, Yamazaki T, Clynes R, Kurosaki T, Greenberg S.

J Immunol. 2011 Jul 15;187(2):619-25. doi: 10.4049/jimmunol.0903425. Epub 2011 Jun 17.

31.

B cell therapy is β-tested: Rituximab puts a pause on β-cell destruction.

Clynes R.

Islets. 2010 Mar-Apr;2(2):130-2. doi: 10.4161/isl.2.2.11452. No abstract available.

PMID:
21099307
32.

Therapeutic targeting of Syk in autoimmune diabetes.

Colonna L, Catalano G, Chew C, D'Agati V, Thomas JW, Wong FS, Schmitz J, Masuda ES, Reizis B, Tarakhovsky A, Clynes R.

J Immunol. 2010 Aug 1;185(3):1532-43. doi: 10.4049/jimmunol.1000983. Epub 2010 Jul 2. Erratum in: J Immunol. 2011 Aug 1;187(3):1516.

33.

CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues.

Budhu S, Loike JD, Pandolfi A, Han S, Catalano G, Constantinescu A, Clynes R, Silverstein SC.

J Exp Med. 2010 Jan 18;207(1):223-35. doi: 10.1084/jem.20091279. Epub 2010 Jan 11.

34.

Dominant expression of the inhibitory FcgammaRIIB prevents antigen presentation by murine plasmacytoid dendritic cells.

Flores M, Desai DD, Downie M, Liang B, Reilly MP, McKenzie SE, Clynes R.

J Immunol. 2009 Dec 1;183(11):7129-39. doi: 10.4049/jimmunol.0901169. Epub 2009 Nov 16.

35.

RAGE ligation affects T cell activation and controls T cell differentiation.

Chen Y, Akirav EM, Chen W, Henegariu O, Moser B, Desai D, Shen JM, Webster JC, Andrews RC, Mjalli AM, Rothlein R, Schmidt AM, Clynes R, Herold KC.

J Immunol. 2008 Sep 15;181(6):4272-8.

36.
37.

Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II.

Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L, Flores M, Li N, Schweighoffer E, Greenberg S, Tybulewicz V, Vignali D, Clynes R.

J Immunol. 2008 May 1;180(9):5916-26.

38.

Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response.

Clynes R, Moser B, Yan SF, Ramasamy R, Herold K, Schmidt AM.

Curr Mol Med. 2007 Dec;7(8):743-51. Review.

PMID:
18331232
39.

RAGE: exacting a toll on the host in response to polymicrobial sepsis and Listeria monocytogenes.

Clynes R, Herold K, Schmidt AM.

Crit Care. 2007;11(6):183. doi: 10.1186/cc6193. Review.

40.

Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo.

Moser B, Desai DD, Downie MP, Chen Y, Yan SF, Herold K, Schmidt AM, Clynes R.

J Immunol. 2007 Dec 15;179(12):8051-8.

41.

Protective mechanisms of IVIG.

Clynes R.

Curr Opin Immunol. 2007 Dec;19(6):646-51. Epub 2007 Nov 26. Review. No abstract available.

PMID:
18032008
42.

Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy.

Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, Vahdat L, Cheng B, Pegram M, Knutson KL, Clynes R.

Clin Cancer Res. 2007 Sep 1;13(17):5133-43.

43.

Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress.

Herold K, Moser B, Chen Y, Zeng S, Yan SF, Ramasamy R, Emond J, Clynes R, Schmidt AM.

J Leukoc Biol. 2007 Aug;82(2):204-12. Epub 2007 May 18. Review.

PMID:
17513693
44.

Antigenic targeting of the human mannose receptor induces tumor immunity.

He LZ, Crocker A, Lee J, Mendoza-Ramirez J, Wang XT, Vitale LA, O'Neill T, Petromilli C, Zhang HF, Lopez J, Rohrer D, Keler T, Clynes R.

J Immunol. 2007 May 15;178(10):6259-67.

45.

Fc gamma receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T cell responses.

Desai DD, Harbers SO, Flores M, Colonna L, Downie MP, Bergtold A, Jung S, Clynes R.

J Immunol. 2007 May 15;178(10):6217-26.

46.

Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance.

Harbers SO, Crocker A, Catalano G, D'Agati V, Jung S, Desai DD, Clynes R.

J Clin Invest. 2007 May;117(5):1361-9. Epub 2007 Apr 19.

47.

IVIG therapy: interfering with interferon-gamma.

Clynes R.

Immunity. 2007 Jan;26(1):4-6. Review.

48.

Mouse models of IgG- and IgM-mediated hemolysis.

Schirmer DA, Song SC, Baliff JP, Harbers SO, Clynes RA, Krop-Watorek A, Halverson GR, Czerwinski M, Spitalnik SL.

Blood. 2007 Apr 1;109(7):3099-107.

49.

FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis.

Bergtold A, Gavhane A, D'Agati V, Madaio M, Clynes R.

J Immunol. 2006 Nov 15;177(10):7287-95.

50.

Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity.

Clynes R.

Hematol Oncol Clin North Am. 2006 Jun;20(3):585-612. Review.

PMID:
16762726

Supplemental Content

Loading ...
Support Center